Tonghua Dongbao Pharmaceutical's latest marketcap:
As of 11/06/2025, Tonghua Dongbao Pharmaceutical's market capitalization has reached $2.48 B. According to our data, Tonghua Dongbao Pharmaceutical is the 5744th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2.48 B |
| Revenue (ttm) | 385.02 M |
| Net Income (ttm) | 172.17 M |
| Shares Out | 1.94 B |
| EPS (ttm) | 0.09 |
| Forward PE | 34.92 |
| Ex-Dividend Date | 06/25/2025 |
| Earnings Date | 10/24/2025 |
Tonghua Dongbao Pharmaceutical's yearly market capitalization.
| Date | Market Cap(¥) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 11/06/2025 | ¥17.65 B | $2.48 B | 12.81% | 5744 |
| 12/31/2024 | ¥15.71 B | $2.15 B | -26.86% | 5419 |
| 12/29/2023 | ¥21.48 B | $3.03 B | 17.97% | 4240 |
| 12/30/2022 | ¥18.21 B | $2.64 B | -17.83% | 4426 |
| 12/31/2021 | ¥22.16 B | $3.49 B | -17.92% | 4280 |
| 12/31/2020 | ¥27 B | $4.14 B | 4.93% | 3296 |
| 12/31/2019 | ¥25.73 B | $3.69 B | -8.99% | 3002 |
| 12/28/2018 | ¥28.27 B | $4.11 B | -27.82% | 2387 |
| 12/29/2017 | ¥39.17 B | $6.02 B | 25.62% | 2019 |
| 12/30/2016 | ¥31.18 B | $4.49 B | 1.04% | 2089 |
Company Profile
Tonghua Dongbao Pharmaceutical Co., Ltd.
Tonghua Dongbao Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company specializing in the research, development, manufacturing, and sale of treatments for diabetes, endocrine disorders, and cardiovascular and cerebrovascular diseases.
Core Offerings
- Diabetes Treatments: Human insulin API and injections, insulin glargine API and injections, insulin aspart API and injections, and liraglutide injections.
- Medical Devices: Insulin pen and needle injection systems, blood sugar monitoring systems, and patient management solutions (online and offline).
- Chemical Drugs: Repaglinide and empagliflozin tablets.
- Other Products: Zhennaoning capsules for diabetes management.
Additional Business Segments
- Building Materials: Plastic steel windows and profiles.
- Real Estate: Engages in property development and management.
Founded in 1985, Tonghua Dongbao Pharmaceutical Co., Ltd. is headquartered in Tonghua, China, and continues to innovate in the healthcare sector.
Frequently Asked Questions
-
What is Tonghua Dongbao Pharmaceutical's (SHA-600867) current market cap?As of 11/06/2025, Tonghua Dongbao Pharmaceutical (including the parent company, if applicable) has an estimated market capitalization of $2.48 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Tonghua Dongbao Pharmaceutical (SHA-600867) rank globally by market cap?Tonghua Dongbao Pharmaceutical global market capitalization ranking is approximately 5744 as of 11/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.